{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:57:55Z","timestamp":1787165875288,"version":"build-2736575974"},"reference-count":178,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.annonc.2021.08.2153","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T11:55:26Z","timestamp":1630929326000},"page":"1537-1551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Therapeutic cancer vaccines revamping: technology advancements and pitfalls"],"prefix":"10.1016","volume":"32","author":[{"given":"G.","family":"Antonarelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ascione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"Mittendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"Disis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6165","key":"10.1016\/j.annonc.2021.08.2153_bib1","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.annonc.2021.08.2153_bib3","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.annonc.2021.08.2153_bib5","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.annonc.2021.08.2153_bib6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3389\/fonc.2018.00315","article-title":"Immuno-oncology: emerging targets and combination therapies","volume":"8","author":"Marshall","year":"2018","journal-title":"Front Oncol"},{"issue":"26","key":"10.1016\/j.annonc.2021.08.2153_bib7","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.annonc.2021.08.2153_bib8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.annonc.2021.08.2153_bib9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.annonc.2021.08.2153_bib10","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.annonc.2021.08.2153_bib11","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A\u00a0guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1146\/annurev-cancerbio-030518-055552","article-title":"Cancer immunotherapy: beyond checkpoint blockade","volume":"3","author":"Dougan","year":"2019","journal-title":"Annu Rev Cancer Biol"},{"issue":"10","key":"10.1016\/j.annonc.2021.08.2153_bib15","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib16","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1038\/s41467-018-06300-3","article-title":"Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA","volume":"9","author":"Paulson","year":"2018","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.annonc.2021.08.2153_bib17","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMoa0811036","article-title":"Loss of mismatched HLA in leukemia after stem-cell transplantation","volume":"361","author":"Vago","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.annonc.2021.08.2153_bib18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/1078-0432.CCR-20-0245","article-title":"The changing landscape of therapeutic cancer vaccines\u2014novel platforms and neoantigen identification","volume":"27","author":"Jou","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.annonc.2021.08.2153_bib19","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: moving beyond current vaccines","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.annonc.2021.08.2153_bib20","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.annonc.2021.08.2153_bib21","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1158\/1078-0432.CCR-21-0079","article-title":"How did we get a COVID-19 vaccine in less than 1 year?","volume":"27","author":"Wherry","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"NPJ Vaccines"},{"issue":"27","key":"10.1016\/j.annonc.2021.08.2153_bib23","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.annonc.2021.08.2153_bib24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.annonc.2021.08.2153_bib25","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.08.2153_bib26","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1056\/NEJMoa2104983","article-title":"Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons","volume":"384","author":"Shimabukuro","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.annonc.2021.08.2153_bib27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.2153_bib28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A\u00a0guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.2153_bib29","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ymthe.2020.09.038","article-title":"Personalized cancer vaccines: clinical landscape, challenges, and opportunities","volume":"29","author":"Shemesh","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.annonc.2021.08.2153_bib30","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40425-015-0093-x","article-title":"A\u00a0quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial","volume":"3","author":"Tan","year":"2015","journal-title":"J\u00a0Immunother Cancer"},{"issue":"6","key":"10.1016\/j.annonc.2021.08.2153_bib31","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S1470-2045(16)00099-1","article-title":"Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Vansteenkiste","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2021.08.2153_bib32","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S1470-2045(14)70236-0","article-title":"Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial","volume":"15","author":"Middleton","year":"2014","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2021.08.2153_bib33","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1470-2045(04)01610-9","article-title":"Part I: Vaccines for solid tumours","volume":"5","author":"Mocellin","year":"2004","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.2153_bib34","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/ncponc0098","article-title":"Recent developments in therapeutic cancer vaccines","volume":"2","author":"Morse","year":"2005","journal-title":"Nat Clin Pract Oncol"},{"issue":"334","key":"10.1016\/j.annonc.2021.08.2153_bib35","doi-asserted-by":"crossref","first-page":"334ps9","DOI":"10.1126\/scitranslmed.aaf0685","article-title":"The Human Vaccines Project: a roadmap for cancer vaccine development","volume":"8","author":"Romero","year":"2016","journal-title":"Sci Transl Med"},{"issue":"43","key":"10.1016\/j.annonc.2021.08.2153_bib36","doi-asserted-by":"crossref","first-page":"18545","DOI":"10.1073\/pnas.1010978107","article-title":"Accumulation of driver and passenger mutations during tumor progression","volume":"107","author":"Bozic","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7793","key":"10.1016\/j.annonc.2021.08.2153_bib37","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"Pan-cancer analysis of whole genomes","volume":"578","author":"Campbell","year":"2020","journal-title":"Nature"},{"issue":"7662","key":"10.1016\/j.annonc.2021.08.2153_bib38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"issue":"6236","key":"10.1016\/j.annonc.2021.08.2153_bib39","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1126\/science.aaa3828","article-title":"Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells","volume":"348","author":"Carreno","year":"2015","journal-title":"Science"},{"issue":"7662","key":"10.1016\/j.annonc.2021.08.2153_bib40","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"issue":"7738","key":"10.1016\/j.annonc.2021.08.2153_bib41","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","article-title":"Actively personalized vaccination trial for newly diagnosed glioblastoma","volume":"565","author":"Hilf","year":"2019","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.annonc.2021.08.2153_bib42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.2153_bib43","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41591-021-01233-9","article-title":"Intratumoral heterogeneity in cancer progression and response to immunotherapy","volume":"27","author":"Vitale","year":"2021","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.2153_bib44","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2021.08.2153_bib45","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.tcb.2019.01.003","article-title":"Mutational and antigenic landscape in tumor progression and cancer immunotherapy","volume":"29","author":"Vitale","year":"2019","journal-title":"Trends Cell Biol"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib46","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1038\/s41467-020-16295-5","article-title":"Genetic and epigenetic intratumor heterogeneity impacts prognosis of lung adenocarcinoma","volume":"11","author":"Hua","year":"2020","journal-title":"Nat Commun"},{"issue":"6190","key":"10.1016\/j.annonc.2021.08.2153_bib47","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1126\/science.1254257","article-title":"Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma","volume":"344","author":"Patel","year":"2014","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.annonc.2021.08.2153_bib48","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/0008-5472.CAN-16-2822","article-title":"Genomic and epigenomic heterogeneity of hepatocellular carcinoma","volume":"77","author":"Lin","year":"2017","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.annonc.2021.08.2153_bib49","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/nm.4125","article-title":"Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia","volume":"22","author":"Li","year":"2016","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.annonc.2021.08.2153_bib50","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/j.cell.2021.03.009","article-title":"Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes","volume":"184","author":"Dentro","year":"2021","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.annonc.2021.08.2153_bib51","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","article-title":"Intratumor heterogeneity: the rosetta stone of therapy resistance","volume":"37","author":"Marusyk","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.annonc.2021.08.2153_bib52","doi-asserted-by":"crossref","first-page":"629722","DOI":"10.3389\/fimmu.2020.629722","article-title":"Tumor burden and immunotherapy: impact on immune infiltration and therapeutic outcomes","volume":"11","author":"Kim","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib53","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12916-019-1326-5","article-title":"Recent advances in triple negative breast cancer: the immunotherapy era","volume":"17","author":"Marra","year":"2019","journal-title":"BMC Med"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.2153_bib54","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41571-019-0317-y","article-title":"Frontline immunotherapy for NSCLC\u2014the tale of the tail","volume":"17","author":"Chiang","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2021.08.2153_bib55","doi-asserted-by":"crossref","first-page":"e146956","DOI":"10.1172\/JCI146956","article-title":"Vaccines for immunoprevention of cancer","volume":"131","author":"Enokida","year":"2021","journal-title":"J\u00a0Clin Invest"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2021.08.2153_bib56","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1111\/j.1524-4741.2010.01002.x","article-title":"Immunoprevention and immunotherapy of mammary carcinoma","volume":"16","author":"Lollini","year":"2010","journal-title":"Breast J"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.2153_bib57","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/cmi.2017.92","article-title":"Multi-epitope vaccines: a promising strategy against tumors and viral infections","volume":"15","author":"Zhang","year":"2018","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12943-021-01348-0","article-title":"mRNA therapeutics in cancer immunotherapy","volume":"20","author":"Beck","year":"2021","journal-title":"Mol Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.2153_bib59","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.clim.2012.01.015","article-title":"Immunodominance: a pivotal principle in host response to viral infections","volume":"143","author":"Akram","year":"2012","journal-title":"Clin Immunol"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib60","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13046-019-1154-7","article-title":"Cancer DNA vaccines: current preclinical and clinical developments and future perspectives","volume":"38","author":"Lopes","year":"2019","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.annonc.2021.08.2153_bib61","doi-asserted-by":"crossref","first-page":"2","DOI":"10.20517\/2394-4722.2017.52","article-title":"A\u00a0primer on recent developments in cancer immunotherapy, with a focus on neoantigen vaccines","volume":"4","author":"Tokuyasu","year":"2018","journal-title":"J\u00a0Cancer Metastasis Treat"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib62","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/scbi.2001.0401","article-title":"Immunodominance and tumor escape","volume":"12","author":"Schreiber","year":"2002","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib63","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41416-018-0327-z","article-title":"The clinical role of the TME in solid cancer","volume":"120","author":"Giraldo","year":"2019","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib64","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.annonc.2021.08.2153_bib65","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fcell.2018.00028","article-title":"Single cell multi-omics technology: methodology and application","volume":"6","author":"Hu","year":"2018","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib67","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1158\/1078-0432.CCR-18-1749","article-title":"The anatomical location shapes the immune infiltrate in tumors of same etiology and affects survival","volume":"25","author":"Santegoets","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib68","first-page":"1","article-title":"Multiplex bioimaging of single-cell spatial profiles for precision cancer diagnostics and therapeutics","volume":"4","author":"Allam","year":"2020","journal-title":"NPJ Precis Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.08.2153_bib69","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41571-020-00449-x","article-title":"Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy","volume":"18","author":"Gohil","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib70","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.trecan.2019.11.010","article-title":"Tumor functional heterogeneity unraveled by scRNA-seq technologies","volume":"6","author":"Gonz\u00e1lez-Silva","year":"2020","journal-title":"Trends Cancer"},{"issue":"7","key":"10.1016\/j.annonc.2021.08.2153_bib71","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","article-title":"Turning cold into hot: firing up the tumor microenvironment","volume":"6","author":"Duan","year":"2020","journal-title":"Trends Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2021.08.2153_bib72","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1158\/2326-6066.CIR-14-0015","article-title":"Oncolytic viruses and their application to cancer immunotherapy","volume":"2","author":"Chiocca","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"10.1016\/j.annonc.2021.08.2153_bib73","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/ni.1937","article-title":"Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm","volume":"11","author":"Biswas","year":"2010","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib74","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1038\/s41467-018-05315-0","article-title":"Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens","volume":"9","author":"Escobar","year":"2018","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.annonc.2021.08.2153_bib75","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib76","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s40425-019-0755-1","article-title":"Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors","volume":"7","author":"Zhu","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"6","key":"10.1016\/j.annonc.2021.08.2153_bib77","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.molcel.2020.05.034","article-title":"Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy","volume":"78","author":"Bader","year":"2020","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib78","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab"},{"issue":"5","key":"10.1016\/j.annonc.2021.08.2153_bib79","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1158\/1078-0432.CCR-18-2882","article-title":"Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan\u2013kynurenine\u2013aryl hydrocarbon axis","volume":"25","author":"Labadie","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.annonc.2021.08.2153_bib80","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.1158\/1078-0432.CCR-15-0420","article-title":"Molecular pathways: targeting IDO1 and other tryptophan dioxygenases for cancer immunotherapy","volume":"21","author":"Zhai","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib81","doi-asserted-by":"crossref","first-page":"1777625","DOI":"10.1080\/2162402X.2020.1777625","article-title":"Trial watch: IDO inhibitors in cancer therapy","volume":"9","author":"Naour","year":"2020","journal-title":"OncoImmunology"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib82","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40425-018-0409-8","article-title":"Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer","volume":"6","author":"Redman","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2021.08.2153_bib83","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ccell.2020.11.009","article-title":"Immunomodulation by targeted anticancer agents","volume":"39","author":"Petroni","year":"2021","journal-title":"Cancer Cell"},{"issue":"7686","key":"10.1016\/j.annonc.2021.08.2153_bib84","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature25015","article-title":"Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance","volume":"553","author":"Zhang","year":"2018","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.annonc.2021.08.2153_bib85","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1158\/2159-8290.CD-18-0044","article-title":"Mouse models for cancer immunotherapy research","volume":"8","author":"Olson","year":"2018","journal-title":"Cancer Discov"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2021.08.2153_bib86","doi-asserted-by":"crossref","first-page":"TPS788","DOI":"10.1200\/JCO.2020.38.4_suppl.TPS788","article-title":"A\u00a0phase I study to evaluate the safety and tolerability of AB680 combination therapy in participants with gastrointestinal malignancies","volume":"38","author":"Bendell","year":"2020","journal-title":"JCO"},{"issue":"8","key":"10.1016\/j.annonc.2021.08.2153_bib87","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1158\/2159-8290.CD-20-1228","article-title":"Oncogenic KRAS recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis","volume":"11","author":"Kim","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib88","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1038\/s41467-018-07305-8","article-title":"Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression","volume":"9","author":"Calcinotto","year":"2018","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.annonc.2021.08.2153_bib89","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib90","doi-asserted-by":"crossref","first-page":"1898832","DOI":"10.1080\/2162402X.2021.1898832","article-title":"Antitumor efficacy of a neoantigen cancer vaccine delivered by electroporation is influenced by microbiota composition","volume":"10","author":"Lione","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.annonc.2021.08.2153_bib91","author":"Hyeyoon"},{"issue":"4","key":"10.1016\/j.annonc.2021.08.2153_bib92","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib93","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-021-01329-3","article-title":"mRNA in cancer immunotherapy: beyond a source of antigen","volume":"20","author":"van Hoecke","year":"2021","journal-title":"Mol Cancer"},{"key":"10.1016\/j.annonc.2021.08.2153_bib94","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jconrel.2015.12.032","article-title":"Materials for non-viral intracellular delivery of messenger RNA therapeutics","volume":"240","author":"Kauffman","year":"2016","journal-title":"J\u00a0Control Release"},{"issue":"3","key":"10.1016\/j.annonc.2021.08.2153_bib95","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"13","key":"10.1016\/j.annonc.2021.08.2153_bib96","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","article-title":"Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells","volume":"108","author":"Holtkamp","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib97","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol Cancer"},{"key":"10.1016\/j.annonc.2021.08.2153_bib98","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","article-title":"Recent advances in mRNA vaccine technology","volume":"65","author":"Pardi","year":"2020","journal-title":"Curr Opin Immunol"},{"issue":"6525","key":"10.1016\/j.annonc.2021.08.2153_bib99","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1126\/science.aay3638","article-title":"A\u00a0noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis","volume":"371","author":"Krienke","year":"2021","journal-title":"Science"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2021.08.2153_bib100","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1200\/JCO.2020.38.15_suppl.3092","article-title":"A\u00a0phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36\u03b3, for intratumoral (iTu) injection alone and in combination with durvalumab","volume":"38","author":"Patel","year":"2020","journal-title":"JCO"},{"issue":"8","key":"10.1016\/j.annonc.2021.08.2153_bib101","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1080\/21645515.2016.1165908","article-title":"Adenoviral vector-based strategies against infectious disease and cancer","volume":"12","author":"Zhang","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.annonc.2021.08.2153_bib102","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","article-title":"New vaccine technologies to combat outbreak situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front Immunol"},{"issue":"50","key":"10.1016\/j.annonc.2021.08.2153_bib103","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1016\/j.vaccine.2016.06.059","article-title":"Vector-based genetically modified vaccines: exploiting Jenner's legacy","volume":"34","author":"Ramezanpour","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.annonc.2021.08.2153_bib104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2016.06.001","article-title":"Viral vectors as vaccine carriers","volume":"21","author":"Ertl","year":"2016","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.annonc.2021.08.2153_bib105","doi-asserted-by":"crossref","first-page":"16030","DOI":"10.1038\/mtm.2016.30","article-title":"Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens","volume":"3","author":"Afkhami","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"10275","key":"10.1016\/j.annonc.2021.08.2153_bib106","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2021.08.2153_bib107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-4-1","article-title":"A\u00a0phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer","volume":"4","author":"DiPaola","year":"2006","journal-title":"J\u00a0Transl Med"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib108","doi-asserted-by":"crossref","first-page":"e000928","DOI":"10.1136\/jitc-2020-000928","article-title":"Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial","volume":"8","author":"Cappuccini","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"5","key":"10.1016\/j.annonc.2021.08.2153_bib109","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7326\/M15-0880","article-title":"Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention: a randomized trial","volume":"164","author":"Baden","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.annonc.2021.08.2153_bib110","doi-asserted-by":"crossref","first-page":"100009","DOI":"10.1016\/j.jvacx.2019.100009","article-title":"rVSV\u0394G-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with ebola zaire glycoprotein: standardized template with key considerations for a risk\/benefit assessment","volume":"1","author":"Monath","year":"2019","journal-title":"Vaccine X"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib111","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III\u2013IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2021.08.2153_bib112","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.copbio.2019.11.016","article-title":"Design and application of oncolytic viruses for cancer immunotherapy","volume":"65","author":"Yl\u00f6sm\u00e4ki","year":"2020","journal-title":"Curr Opin Biotechnol"},{"issue":"17","key":"10.1016\/j.annonc.2021.08.2153_bib113","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","article-title":"Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas","volume":"384","author":"Friedman","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.annonc.2021.08.2153_bib114","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/mt.2010.103","article-title":"Identification of genetically modified maraba virus as an oncolytic rhabdovirus","volume":"18","author":"Brun","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.annonc.2021.08.2153_bib115","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.omto.2021.02.006","article-title":"Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform","volume":"20","author":"Yl\u00f6sm\u00e4ki","year":"2021","journal-title":"Mol Ther Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2021.08.2153_bib116","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1158\/0008-5472.CAN-19-2062","article-title":"Exploiting preexisting immunity to enhance oncolytic cancer immunotherapy","volume":"80","author":"T\u00e4htinen","year":"2020","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib117","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40425-019-0520-5","article-title":"Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer","volume":"7","author":"Papachristofilou","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"16","key":"10.1016\/j.annonc.2021.08.2153_bib118","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","article-title":"mRNA vaccines manufacturing: challenges and bottlenecks","volume":"39","author":"Rosa","year":"2021","journal-title":"Vaccine"},{"issue":"25","key":"10.1016\/j.annonc.2021.08.2153_bib119","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.annonc.2021.08.2153_bib120","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib121","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.vaccine.2015.10.132","article-title":"A\u00a0novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens","volume":"34","author":"Swaminathan","year":"2016","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.annonc.2021.08.2153_bib122","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.08.2153_bib123","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.annonc.2021.08.2153_bib124","doi-asserted-by":"crossref","first-page":"583287","DOI":"10.3389\/fimmu.2020.583287","article-title":"A\u00a0roadmap toward the definition of actionable tumor-specific antigens","volume":"11","author":"Minati","year":"2020","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.annonc.2021.08.2153_bib125","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.annonc.2020.05.008","article-title":"Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group","volume":"31","author":"De Mattos-Arruda","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2021.08.2153_bib126","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1158\/2326-6066.CIR-13-0227","article-title":"HLA-binding properties of tumor neoepitopes in humans","volume":"2","author":"Fritsch","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.2153_bib127","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.immuni.2017.02.007","article-title":"Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction","volume":"46","author":"Abelin","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.annonc.2021.08.2153_bib128","doi-asserted-by":"crossref","first-page":"100080","DOI":"10.1016\/j.mcpro.2021.100080","article-title":"Sensitive immunopeptidomics by leveraging available large-scale multi-HLA spectral libraries, data-independent acquisition and MS\/MS prediction","volume":"20","author":"Pak","year":"2021","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.annonc.2021.08.2153_bib129","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nbt.4313","article-title":"Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification","volume":"37","author":"Bulik-Sullivan","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.annonc.2021.08.2153_bib130","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s43018-021-00197-6","article-title":"A\u00a0machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types","volume":"2","author":"Gartner","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.annonc.2021.08.2153_bib131","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3389\/fimmu.2020.01581","article-title":"COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning","volume":"11","author":"Ong","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.annonc.2021.08.2153_bib132","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/frai.2020.00065","article-title":"Artificial intelligence for COVID-19 drug discovery and vaccine development","volume":"3","author":"Keshavarzi Arshadi","year":"2020","journal-title":"Front Artif Intell"},{"key":"10.1016\/j.annonc.2021.08.2153_bib133","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1158\/2159-8290.CD-20-1575","article-title":"Exploiting tumor neoantigens to target cancer evolution: current challenges and promising therapeutic approaches","volume":"11","author":"Gupta","year":"2021","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.annonc.2021.08.2153_bib134","doi-asserted-by":"crossref","first-page":"e002071","DOI":"10.1136\/jitc-2020-002071","article-title":"HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy","volume":"9","author":"Marcu","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"7528","key":"10.1016\/j.annonc.2021.08.2153_bib135","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"issue":"470","key":"10.1016\/j.annonc.2021.08.2153_bib136","doi-asserted-by":"crossref","first-page":"eaau5516","DOI":"10.1126\/scitranslmed.aau5516","article-title":"Noncoding regions are the main source of targetable tumor-specific antigens","volume":"10","author":"Laumont","year":"2018","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.annonc.2021.08.2153_bib137","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.annonc.2021.08.2153_bib138","doi-asserted-by":"crossref","first-page":"P316","DOI":"10.1016\/j.ejca.2021.01.046","article-title":"Current perspectives: SARS-CoV-2 vaccines for cancer patients: a call to action","volume":"148","author":"Corti","year":"2021","journal-title":"Eur J Cancer"},{"issue":"7823","key":"10.1016\/j.annonc.2021.08.2153_bib139","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"issue":"7607","key":"10.1016\/j.annonc.2021.08.2153_bib140","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.annonc.2021.08.2153_bib141","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/PPO.0b013e3182325e63","article-title":"Viral vector-based therapeutic cancer vaccines","volume":"17","author":"Larocca","year":"2011","journal-title":"Cancer J"},{"issue":"8","key":"10.1016\/j.annonc.2021.08.2153_bib142","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.ymthe.2021.04.022","article-title":"Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19","volume":"29","author":"Capone","year":"2021","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib143","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1038\/s41467-019-10594-2","article-title":"Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade","volume":"10","author":"D'Alise","year":"2019","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.annonc.2021.08.2153_bib144","doi-asserted-by":"crossref","first-page":"e002374","DOI":"10.1136\/jitc-2021-002374","article-title":"Phase I study of a multitargeted recombinant Ad5 PSA\/MUC-1\/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"9","author":"Bilusic","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"5-6","key":"10.1016\/j.annonc.2021.08.2153_bib145","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41417-018-0019-0","article-title":"Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System\u00ae (RTS\u00ae) gene switch as gene therapy for the treatment of glioma","volume":"25","author":"Barrett","year":"2018","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.annonc.2021.08.2153_bib146","doi-asserted-by":"crossref","first-page":"101430","DOI":"10.1016\/j.smim.2020.101430","article-title":"New viral vectors for infectious diseases and cancer","volume":"50","author":"Sasso","year":"2020","journal-title":"Semin Immunol"},{"issue":"14","key":"10.1016\/j.annonc.2021.08.2153_bib147","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.08.2153_bib148","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.coph.2019.01.007","article-title":"Peptides as cancer vaccines","volume":"47","author":"Calvo Tard\u00f3n","year":"2019","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib149","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1586\/14760584.1.1.111","article-title":"Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines","volume":"1","author":"Aucouturier","year":"2002","journal-title":"Expert Rev Vaccines"},{"issue":"7","key":"10.1016\/j.annonc.2021.08.2153_bib150","doi-asserted-by":"crossref","first-page":"e947892","DOI":"10.4161\/21624011.2014.947892","article-title":"Two in one: improving synthetic long peptide vaccines by combining antigen and adjuvant in one molecule","volume":"3","author":"Zom","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.annonc.2021.08.2153_bib151","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1186\/s12885-019-5725-y","article-title":"Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication","volume":"19","author":"Maynard","year":"2019","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.annonc.2021.08.2153_bib152","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrc2373","article-title":"Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines","volume":"8","author":"Melief","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib153","doi-asserted-by":"crossref","first-page":"17284","DOI":"10.1038\/s41598-020-74187-6","article-title":"TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1\/PD-L1 blockade in HLA-A\u22172402 mice","volume":"10","author":"Tanaka","year":"2020","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.annonc.2021.08.2153_bib154","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1111\/cas.14765","article-title":"First-in-human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors","volume":"112","author":"Kondo","year":"2021","journal-title":"Cancer Sci"},{"issue":"7738","key":"10.1016\/j.annonc.2021.08.2153_bib155","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.2153_bib156","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A\u00a0phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.annonc.2021.08.2153_bib157","author":"Awad"},{"issue":"3","key":"10.1016\/j.annonc.2021.08.2153_bib158","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","article-title":"Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma","volume":"27","author":"Hu","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.2153_bib159","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41541-020-0159-8","article-title":"The promise of mRNA vaccines: a biotech and industrial perspective","volume":"5","author":"Jackson","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"5-6","key":"10.1016\/j.annonc.2021.08.2153_bib160","first-page":"398","article-title":"Extracellular RNA sensing by pattern recognition receptors","volume":"10","author":"Tatematsu","year":"2018","journal-title":"J\u00a0Innate Immun"},{"key":"10.1016\/j.annonc.2021.08.2153_bib161","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1056\/NEJMc2103916","article-title":"Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19","volume":"384","author":"Doria-Rose","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.08.2153_bib162","series-title":"Plotkin's Vaccines","first-page":"51","article-title":"Vaccine manufacturing","author":"Gomez","year":"2018"},{"issue":"6","key":"10.1016\/j.annonc.2021.08.2153_bib163","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.copbio.2007.10.010","article-title":"Replicating and non-replicating viral vectors for vaccine development","volume":"18","author":"Robert-Guroff","year":"2007","journal-title":"Curr Opin Biotechnol"},{"issue":"5","key":"10.1016\/j.annonc.2021.08.2153_bib164","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.chom.2020.04.021","article-title":"The challenges of vaccine development against a new virus during a pandemic","volume":"27","author":"Diamond","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"23","key":"10.1016\/j.annonc.2021.08.2153_bib165","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.1128\/JVI.06048-11","article-title":"A\u00a0double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge","volume":"85","author":"Bolles","year":"2011","journal-title":"J\u00a0Virol"},{"issue":"8","key":"10.1016\/j.annonc.2021.08.2153_bib166","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41577-020-0372-8","article-title":"Optimizing safety surveillance for COVID-19 vaccines","volume":"20","author":"Chandler","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10.1016\/j.annonc.2021.08.2153_bib167","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/14737159.2019.1659728","article-title":"Circulating biomarkers predictive of tumor response to cancer immunotherapy","volume":"19","author":"Lee","year":"2019","journal-title":"Expert Rev Mol Diagn"},{"issue":"3","key":"10.1016\/j.annonc.2021.08.2153_bib168","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","article-title":"Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition","volume":"184","author":"Litchfield","year":"2021","journal-title":"Cell"},{"issue":"D1","key":"10.1016\/j.annonc.2021.08.2153_bib169","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"10229","key":"10.1016\/j.annonc.2021.08.2153_bib170","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","article-title":"Small molecules, big impact: 20 years of targeted therapy in oncology","volume":"395","author":"Bedard","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.annonc.2021.08.2153_bib171","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","article-title":"ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annonc.2021.08.2153_bib172","doi-asserted-by":"crossref","first-page":"524968","DOI":"10.3389\/fimmu.2020.524968","article-title":"The immunogenic potential of recurrent cancer drug resistance mutations: an in silico study","volume":"11","author":"Punta","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.2153_bib173","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in The Cancer Genome Atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.annonc.2021.08.2153_bib174","doi-asserted-by":"crossref","first-page":"a006098","DOI":"10.1101\/cshperspect.a006098","article-title":"Signal transduction in cancer","volume":"5","author":"Sever","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"10.1016\/j.annonc.2021.08.2153_bib175","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(20)30726-9","article-title":"Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study","volume":"22","author":"Syeda","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.08.2153_bib176","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.annonc.2020.12.010","article-title":"Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling","volume":"32","author":"Ococks","year":"2021","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2021.08.2153_bib177","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1172\/JCI80009","article-title":"Therapeutic cancer vaccines","volume":"125","author":"Melief","year":"2015","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"10.1016\/j.annonc.2021.08.2153_bib178","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41571-018-0002-6","article-title":"The emerging clinical relevance of genomics in cancer medicine","volume":"15","author":"Berger","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"D1","key":"10.1016\/j.annonc.2021.08.2153_bib179","first-page":"D948","article-title":"IPD-IMGT\/HLA database","volume":"48","author":"Robinson","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.annonc.2021.08.2153_bib180","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-immunol-082119-124838","article-title":"T\u00a0cell epitope predictions","volume":"38","author":"Peters","year":"2020","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.2153_bib181","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41587-019-0322-9","article-title":"A\u00a0large peptidome dataset improves HLA class I epitope prediction across most of the human population","volume":"38","author":"Sarkizova","year":"2020","journal-title":"Nat Biotechnol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421044574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421044574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:06:37Z","timestamp":1760335597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753421044574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":178,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0923753421044574"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2021.08.2153","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic cancer vaccines revamping: technology advancements and pitfalls","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2021.08.2153","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}